| Name | [Lys8, Lys9]-Neurotensin (8-13) acetate |
| Description | [Lys8, Lys9]-Neurotensin (8-13) acetate, a Neurotensin analog, exerts its analgesic effects through activation of the G protein-coupled receptors NTS1 and NTS2, with Ki values of 0.33 nM and 0.95 nM for hNTS1 and hNTS2 receptors, respectively[1]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 8.21 mg/mL (10 mM), Sonication is recommended.
|
| Keywords | NeurotensinReceptor | Neurotensin Receptor | [Lys-8, Lys9]-Neurotensin (8-13) acetate(139026-64-5 free base) | [Lys8, Lys9]Neurotensin (813) acetate | [Lys8, Lys9]-Neurotensin Acetate | [Lys8, Lys9]-Neurotensin | [Lys8, Lys9] Neurotensin (8 13) acetate |
| Inhibitors Related | Substance P 1-9 aceate | SB-657510 | AF38469 | Kinetensin acetate(103131-69-7 free base) | Meclinertant | SB 611812 | Neurotensin | SBI-553 | Neurotensin(8-13) 3TFA(60482-95-3(free base)) | SORT-PGRN interaction inhibitor 1 | (±)-AC 7954 hydrochloride | Urantide acetate(669089-53-6 free base) |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Peptide Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |